Your session is about to expire
← Back to Search
Enzalutamide + Abiraterone + Prednisone for Prostate Cancer
Study Summary
This trial is to study the long-term safety of subjects who are still benefiting from treatment with Enzalutamide.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I need new treatment for my cancer, but not one I've had before.I can keep taking the same cancer treatment I was on before, unless my doctor changes it.I need new systemic therapy for my cancer, but not treatments I've had before.I am currently in a trial and taking enzalutamide.I am currently in a trial and taking enzalutamide.My cancer got worse while I was on enzalutamide in a study.I am not currently on any experimental treatments except for enzalutamide.I am currently on enzalutamide for breast cancer in an Astellas or Medivation/Pfizer study and it's working for me.I am not able to have children, or I can and will follow strict birth control measures during the study.My partner and I use two forms of birth control, including a barrier method, and will continue for 3 months after my last dose.I agree not to donate sperm during and for 3 months after the study.I can swallow capsules and follow the study's rules.I am not currently on any clinical trial treatments except for enzalutamide.I am currently on enzalutamide for prostate cancer in an Astellas or Medivation study and it's working for me.I can swallow capsules and follow the study's rules.
- Group 1: enzalutamide
- Group 2: enzalutamide plus abiraterone acetate and prednisone
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there still vacancies for participants in this experiment?
"Affirmative. Clinicaltrials.gov data affirms that this clinical trial, which first appeared on December 22nd 2016, is currently soliciting participants. The study requires 900 persons to be recruited from 1 site."
What other trials have been conducted to assess the impact of enzalutamide?
"Currently, there are 437 active studies analyzing the efficacy of enzalutamide, with 119 being in Phase 3. Although most research sites for this drug can be found in Germantown, Tennessee; a total of 21159 centres across the world have been enrolled to undertake these trials."
What primary indications are addressed with enzalutamide therapy?
"Enzalutamide is often prescribed for thyroiditis, but it also possesses properties that make it a viable treatment option for ulcerative colitis, cancerous tumours, and varicella-zoster virus acute retinal necrosis."
Has enzalutamide received the necessary clearance from the FDA?
"With regards to safety, enzalutamide has been awarded a score of 2 as there is some evidence that it can be administered without causing harm yet no clinical data showing the drug's efficacy."
What is the exact number of people enrolled in this experiment?
"Affirmative. According to the clinicaltrials.gov website, this research program is accepting participants at present; it was originally posted on December 22nd 2016 and has been recently updated on September 29th 2022. 900 individuals are needed for this study which will take place in a single location."
Share this study with friends
Copy Link
Messenger